

Summit Therapeutics plc
("Summit" or the "Company")

SUMMIT TO PRESENT AT NEEDHAM AND COMPANY'S ANNUAL HEALTHCARE CONFERENCE

Oxford, UK, 7 April 2015 – Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and *C. difficile* infection, announces that Mr Glyn Edwards, Summit's Chief Executive Officer, is scheduled to present at Needham and Company's 14th Annual Healthcare Conference at 11:20am EDT (4:20pm BST) on 15th April 2015 in New York City.

A live audio webcast of the presentation, and a copy of the slides, will be available through the Investors section of Summit's website. A replay of the webcast will be available soon after the live presentation.

- END -

About Summit Therapeutics

Summit is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease *C. difficile* infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter ([@summitplc](https://twitter.com/summitplc)).

For more information, please contact:

Summit Therapeutics

Glyn Edwards / Richard Pye (UK office)
Erik Ostrowski (US office)

Tel: +44 (0)1235 443 951
+1 617 294 6607

Cairn Financial Advisers LLP

(Nominated Adviser)
Liam Murray / Tony Rawlinson

Tel: +44 (0)20 7148 7900

N+1 Singer

(Broker)
Aubrey Powell / Jen Boorer

Tel: +44 (0)20 7496 3000

MacDougall Biomedical Communications

(US media contact)
Michelle Avery

Tel: +1 781 235 3060
mavery@macbiocom.com

Peckwater PR

(Financial public relations, UK)
Tarquin Edwards

Tel: +44 (0)7879 458 364
tarquin.edwards@peckwaterpr.co.uk